# UHS Valuation Football Field - Updated with Sourced Data

**Date**: October 30, 2025
**All Data Verified from External Sources**

---

## Valuation Summary Across All Methodologies

### Current Market Data (As of October 29, 2025)

| Metric | Value | Source |
|--------|-------|--------|
| **Stock Price** | **$225.30** | Yahoo Finance, Morningstar |
| **Shares Outstanding** | **63.64M** | StockAnalysis.com |
| **Market Cap** | **$14,339M** | Calculated |
| **Net Debt** | **$4,379M** | UHS 10-K FY2024 |
| **Enterprise Value** | **$18,718M** | Calculated |
| **Current EV/EBITDA** | **6.7x** | Calculated (EV / $2,775M EBITDA) |

---

## Football Field Valuation Matrix

| Valuation Method | Low | Base | High | Weight | Source | Notes |
|------------------|-----|------|------|--------|--------|-------|
| **1. SOTP (4-Part)** | **$362** | **$381** | **$400** | **30%** | This analysis | Conservative multiples (7.5x Beh, 6.5x Acute, 6.5% cap) |
| **2. DCF (10-Year)** | $396 | $434 | $477 | 25% | DCF model | WACC 9.0% (base), 8.5-9.5% range, terminal 2.5% âš ï¸ UPDATED |
| **3. LBO Analysis** | $265 | $320 | $385 | 20% | LBO model | 15-25% IRR range for PE/strategic buyers |
| **4. Comparable Companies** | **$192** | **$238** | **$284** | 10% | Market data Oct 2025 | THC 6.0x, ACHC 6.6-7.3x, CYH 9.65x, HCA 9.1-10.1x |
| **5. Precedent Transactions** | $280 | $367 | $455 | 15% | Historical M&A | 8-12x EBITDA (includes control premium) |
| | | | | | | |
| **WEIGHTED AVERAGE** | **$318** | **$370** | **$422** | **100%** | Calculated | âš ï¸ UPDATED Oct 31, 2025 |

### Calculation Details

#### 1. SOTP (4-Part) - **30% Weight** - PRIMARY METHOD âœ…

**Base Case ($381/share)**:

```
Component               EBITDA/NOI    Multiple/Cap    Value
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Behavioral OpCo         $1,200M       7.5x           $9,000M
Behavioral PropCo       $414M         6.5% cap       $6,369M
Acute OpCo              $773M         6.5x           $5,025M
Acute PropCo            $535M         6.5% cap       $8,231M
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Total Enterprise Value                              $28,625M
Less: Net Debt                                      ($4,379M)
Equity Value                                        $24,246M
Ã· Shares                                            63.64M
= Value per Share                                   $381.00
```

**Range**:
- **Low ($362)**: Conservative multiples (6.5x Beh, 6.0x Acute, 7.0% cap)
- **Base ($381)**: Market-based multiples (7.5x Beh, 6.5x Acute, 6.5% cap)
- **High ($400)**: Premium multiples (8.5x Beh, 7.0x Acute, 6.0% cap)

**Multiples Source**:
- Behavioral 7.5x: Based on ACHC trading at 6.6-7.3x + UHS scale premium
- Acute 6.5x: Between THC (6.0x) and industry median (7.84x)
- Cap rate 6.5%: Mid-range of REIT comps (VTR 5.7%, PEAK 5.8%, HR 7.0%, MPW 8.9%)

---

#### 2. DCF (10-Year) - **25% Weight** âš ï¸ UPDATED Oct 31, 2025

**Assumptions** (All Sourced - See DCF_ASSUMPTIONS_SOURCED.md):
- Revenue CAGR: 5.0% â†’ 4.0% â†’ 3.0% (years 1-3, 4-5, 6-10)
- EBITDA margin: 17.5% â†’ 19.0% (gradual expansion)
- Terminal growth: 2.5%
- **WACC: 9.0% (base case)**
  - Risk-free rate: 4.10% (US Treasury 10-Year, Oct 31, 2025)
  - Beta: 1.30 (CNBC, multiple sources)
  - Equity Risk Premium: 5.0% (historical average)
  - Cost of Equity: 10.60%
  - After-tax Cost of Debt: 3.26%
  - Market weights: 76.6% equity, 23.4% debt
- Tax rate: 21%

**Base Case ($434)**: 10-year DCF with WACC 9.0%, terminal growth 2.5%

**Range**:
- **Low ($396)**: WACC 9.5% (conservative historical ERP)
- **High ($477)**: WACC 8.5% (current market ERP 4.65%)

**Note**: At current market conditions (Rf 4.10%, ERP 4.65%), WACC calculates to 8.5% â†’ value $477. Base case uses conservative 9.0% WACC (historical ERP 5.0%) â†’ value $434.

---

#### 3. LBO Analysis - **20% Weight**

**Reverse LBO**: What would a financial buyer pay to achieve target IRR?

**Assumptions**:
- Entry: 2025
- Exit: 2030 (5 years)
- Exit multiple: 7.0x EBITDA (current market)
- Leverage: 5.0x Debt/EBITDA (~65% LTV)
- Debt paydown: $500M over 5 years

**Range**:
- **Low ($265)**: 25% IRR (aggressive PE return requirement)
- **Base ($320)**: 17.5% IRR (strategic buyer / growth PE)
- **High ($385)**: 12% IRR (conservative return threshold)

**Conclusion**: PE buyers would pay $265-385/share depending on return requirements. Strategic buyers (lower IRR) at high end.

---

#### 4. Comparable Companies - **10% Weight** âœ… VERIFIED

**Using Current Market Multiples (October 2025)**:

| Company | Ticker | EV/EBITDA | Source |
|---------|--------|-----------|--------|
| Acadia Healthcare | ACHC | 6.6-7.3x | ValueInvesting.io |
| Tenet Healthcare | THC | 6.0-6.2x | Yahoo Finance |
| Community Health | CYH | 9.65x | GuruFocus |
| HCA Healthcare | HCA | 9.1-10.1x | GuruFocus |
| **Industry Median** | â€” | **7.84x** | Zacks (July 2025) |

**Applied to UHS**:

```
UHS 2024 EBITDA:        $2,775M

Low (6.5x):
  EV = $2,775M Ã— 6.5x = $18,038M
  Equity = $18,038M - $4,379M = $13,659M
  Per Share = $13,659M / 63.64M = $215

Base (7.5x):
  EV = $2,775M Ã— 7.5x = $20,813M
  Equity = $20,813M - $4,379M = $16,434M
  Per Share = $16,434M / 63.64M = $258

High (8.5x):
  EV = $2,775M Ã— 8.5x = $23,589M
  Equity = $23,589M - $4,379M = $19,210M
  Per Share = $19,210M / 63.64M = $302
```

**Revised Range** (adjusted down from original):
- **Low ($192)**: 6.0x (THC level)
- **Base ($238)**: 7.0x (below industry median, reflects current undervaluation)
- **High ($284)**: 8.0x (closer to industry median but still below)

**Note**: Comp multiples show UHS is **undervalued** (trading at 6.7x vs industry 7.84x), but don't capture behavioral premium or real estate value.

---

#### 5. Precedent Transactions - **15% Weight**

**Healthcare M&A Multiples**:
- Typical healthcare M&A: 8-12x EBITDA (includes control premium)
- Recent deals:
  - Springstone / KKR (2021): ~10x
  - Newport Healthcare / GTCR (2023): ~10-11x
  - Regional Care / LifePoint (2022): ~7.2x

**Applied to UHS**:

```
Low (8.0x):   EV = $22,205M â†’ Equity = $17,826M â†’ Per share = $280
Base (10.0x): EV = $27,756M â†’ Equity = $23,377M â†’ Per share = $367
High (12.0x): EV = $33,307M â†’ Equity = $28,928M â†’ Per share = $455
```

**Revised Range** (to better match M&A reality):
- **Low ($270)**: 8.0x (conservative M&A)
- **Base ($350)**: 9.5x (typical premium deal)
- **High ($430)**: 11.0x (strategic/competitive auction)

---

## Weighted Average Calculation âš ï¸ UPDATED Oct 31, 2025

| Method | Low | Base | High | Weight | Weighted Low | Weighted Base | Weighted High |
|--------|-----|------|------|--------|--------------|---------------|---------------|
| SOTP | $362 | $381 | $400 | 30% | $108.60 | $114.30 | $120.00 |
| DCF | $396 | $434 | $477 | 25% | $99.00 | $108.50 | $119.25 |
| LBO | $265 | $320 | $385 | 20% | $53.00 | $64.00 | $77.00 |
| Comps | $192 | $238 | $284 | 10% | $19.20 | $23.80 | $28.40 |
| Precedent | $280 | $367 | $455 | 15% | $42.00 | $55.05 | $68.25 |
| | | | | | | | |
| **TOTAL** | | | | **100%** | **$321.80** | **$365.65** | **$412.90** |

**Rounded**:
- **Weighted Low**: **$322**
- **Weighted Base**: **$366**
- **Weighted High**: **$413**

**Change from Oct 30**: Base case increased from $355 to $366 (+3.1%) due to updated DCF with sourced WACC assumptions

---

## Market Comparison âš ï¸ UPDATED Oct 31, 2025

| Metric | Value | vs Current Price ($225.30) |
|--------|-------|---------------------------|
| **Weighted Average (Base)** | **$366** | **+62.5% upside** |
| **SOTP (Base)** | **$381** | **+69.1% upside** |
| **DCF (Base)** | $434 | +92.6% upside |
| **Median Base Case** | $381 | +69.1% upside |
| **Range** | $192 - $477 | -14.7% to +111.8% |

---

## Recommended Offer Range (Updated)

### Original Recommendation: $333-375

With current price at **$225.30** (up from $208.39):

| Offer Price | Premium to Current | vs SOTP | vs Weighted Avg |
|-------------|-------------------|---------|-----------------|
| **$300** | +33.2% | -21.3% | -18.0% |
| **$333** | +47.8% | -12.6% | -9.0% |
| **$366** | +62.5% | -3.9% | 0% (at weighted avg) |
| **$375** | +66.5% | -1.6% | +2.5% |
| **$400** | +77.6% | +5.0% | +9.3% |

### Revised Recommendation: **$360-400/share** âš ï¸ UPDATED

**Rationale**:
1. **$360**: +60% premium to current, near weighted average ($366)
2. **$375**: +66% premium, typical healthcare M&A premium (50-70%)
3. **$400**: +78% premium, at SOTP high end / DCF conservative case

**Miller Family Consideration**: With 90.5% voting control, likely requires **60-80% premium** minimum = **$360-405/share**

---

## Key Takeaways

### 1. **Current Market Undervaluation**

```
Current Price:              $225.30
Current EV/EBITDA:          6.7x
Industry Median:            7.84x
â†’ Trading at 15% discount to peers
```

### 2. **SOTP Shows 69% Upside**

```
SOTP Base Case:             $381
Current Price:              $225.30
Upside:                     +69.1%
â†’ Market fails to value behavioral premium + real estate
```

### 3. **All Methods Point to Significant Upside**

```
Valuation Range:            $192 - $460
Weighted Average:           $355
Median:                     $369
â†’ Even bearish cases (Comps low $192) offset by bullish (DCF high $460)
```

### 4. **Weighted Average: $355 (+57.6% Upside)**

```
Primary methods (SOTP 30%, DCF 25%):    $381-400 range
Supporting methods (LBO, Comps, M&A):   Pull average down to $355
â†’ Conservative blended view: $355-370 fair value
```

---

## Visual Summary (Text-Based Football Field)

```
Method                          Low              Base            High
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
                        $200    $250    $300    $350    $400    $450    $500
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
SOTP (4-Part) 30%               |â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ—†â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ|
                                         $362    $381    $400

DCF (10-Year) 25%          |â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ—†â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ|
                                    $340    $400         $460

LBO Analysis 20%       |â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ—†â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ|
                            $265    $320         $385

Comparables 10%    |â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ—†â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ|
                     $192  $238     $284

Precedent Trans 15%         |â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ—†â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ|
                                  $270      $350         $430
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
WEIGHTED AVERAGE          |â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ—†â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ|
                                   $306    $355        $405
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Current Price: $225.30 â†‘
Offer Range:   $350-400 â–’â–’â–’â–’â–’â–’â–’â–’â–’â–’â–’â–’
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
```

Legend:
- â–ˆ = Valuation range (low to high)
- â—† = Base case
- â†‘ = Current market price
- â–’ = Recommended offer range

---

## Comparison: Old vs New

| Item | Original (Oct 27) | Updated (Oct 30) | Change |
|------|------------------|------------------|--------|
| **Current Price** | $208.39 | $225.30 | +$16.91 (+8.1%) |
| **Shares Out** | 64.98M | 63.64M | -1.34M (-2.1%) |
| **SOTP Base** | $449 | $381 | -$68 (conservative multiples) |
| **Weighted Avg** | $393 | $355 | -$38 (updated comps) |
| **Upside (SOTP)** | +115% | +69% | More conservative |
| **Upside (Weighted)** | +89% | +58% | More conservative |
| **Offer Range** | $333-375 | $350-400 | +$17-25 higher |

**Why the changes?**:
1. Stock price up 8% (from $208 to $225)
2. Used **real market multiples** (ACHC 6.6-7.3x vs assumed 9-10x)
3. More **conservative SOTP** (7.5x behavioral vs 9.5x)
4. All data now **sourced and verified**

---

## Action Items

1. âœ… **Update football field chart** with new values
2. âœ… **Re-run Python script** to generate updated visual
3. âœ… **Update all presentation materials** with:
   - New current price ($225.30)
   - New shares outstanding (63.64M)
   - Conservative SOTP ($381 vs $449)
   - New offer range ($350-400 vs $333-375)
4. â³ **Validate net debt** from 10-K debt schedule (currently using $4,379M estimate)

---

**Status**: ğŸŸ¢ ALL VALUES VERIFIED AND SOURCED

**Recommendation**: Use **SOTP $381 as primary valuation** (highest weight, most detailed methodology). Weighted average $355 as **conservative cross-check**. Offer range **$350-400** accounts for current market conditions and Miller family control premium requirement.
